- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Eli Lilly diabetes drug Mounjaro won UK watchdog backing: Bloomberg
Britain: Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.Mounjaro is expected to become a blockbuster treatment if it is also approved to treat obesity and a U.S. decision on its use for weight loss is expected later this year.Bloomberg News quoted Helen Knight, director of...
Britain: Eli Lilly's drug Mounjaro has won the backing of Britain's drug cost-effectiveness watchdog as a diabetes treatment, Bloomberg News reported on Thursday.
Mounjaro is expected to become a blockbuster treatment if it is also approved to treat obesity and a U.S. decision on its use for weight loss is expected later this year.
Bloomberg News quoted Helen Knight, director of medicines evaluation at the National Institute for Health and Care Excellence (NICE) as saying that Mounjaro has the potential to "provide an effective and good value treatment option" for people with type 2 diabetes that isn't well controlled by other drugs.
NICE and Lilly did not immediately respond to a Reuters request for comment.
Earlier in July, NICE did not recommend Mounjaro, also known as tirzepatide, saying more evidence was needed before it could be used by the National Health Service. NICE asked Lilly for more data on whether the drug resulted in better weight loss than other drugs belonging to the same class of treatments.
Read also: Europe to face shortage of Eli Lilly diabetes drug Trulicity through September
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751